Prilocard 2.5 mg Tablets for Dogs

Country: Ingilterra

Lingwa: Ingliż

Sors: VMD (Veterinary Medicines Directorate)

Ingredjent attiv:

Ramipril

Disponibbli minn:

aniMedica GmbH

Kodiċi ATC:

QC09AA05

INN (Isem Internazzjonali):

Ramipril

Għamla farmaċewtika:

Tablet

Tip ta 'preskrizzjoni:

POM-V - Prescription Only Medicine – Veterinarian

Grupp terapewtiku:

Dogs

Żona terapewtika:

Cardio Vascular ACE inhibitor

L-istatus ta 'awtorizzazzjoni:

Expired

Data ta 'l-awtorizzazzjoni:

2012-07-18

Karatteristiċi tal-prodott

Revised: March 2017
AN: 00125/2016
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Prilocard 2.5mg tablets for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
Active substance:
Ramipril 2.5 mg
Excipients:
yellow ferric oxide 0.40 mg (E172)
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablets.
Light yellow capsule-shaped biconvex tablets scored on one side of the
tablet and
imprinted with 'B' and '49' on either side of the scoring line. The
scoreline is only to
facilitate breaking for ease of swallowing and not to divide into
equal doses.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For
treatment
of
congestive
heart
failure
(equivalent
to
New
York
Heart
Association [NYHA] classes II, III and IV) caused by valvular
insufficiency due to
endocardiosis
or
cardiomyopathy.
The
preparation
may
if
applicable
be
administered
concomitantly
with
furosemide
(diuretic)
and/or
the
cardiac
glycosides digoxin or methyl digoxin.
Class
Clinical symptoms
II
Fatigue, dyspnoea, cough etc. seen in normal activity.
Ascites may occur at this stage.
III
Comfortable at rest, but capacity for activity minimal.
IV
Incapable of any activity.
Clinical symptoms of disablement occur even at rest.
Revised: March 2017
AN: 00125/2016
Page 2 of 6
In patients treated concomitantly with ramipril and furosemide, the
diuretic dose
may
be
reduced
to
achieve
the
same
diuretic
effect
as
in
treatment
with
furosemide alone.
4.3
CONTRAINDICATIONS
Do not use in haemodynamically-related stenoses (e.g. aortic stenosis,
mitral
stenosis) nor in cases of obstructive hypertrophic cardiomyopathy.
Do not use in cases of hypersensitivity to the active substance,
ACE-inhibitors or
to any of the excipient(s).
See Section 4.7 for use in Pregnancy and Lactation
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
If symptoms of apathy and ataxia (potentia